81,250 Shares in Eyenovia, Inc. (NASDAQ:EYEN) Bought by Financial Management Network Inc.

Financial Management Network Inc. acquired a new stake in Eyenovia, Inc. (NASDAQ:EYEN) in the third quarter, Holdings Channel reports. The firm acquired 81,250 shares of the company’s stock, valued at approximately $39,000.

Several other large investors have also bought and sold shares of the stock. Armistice Capital LLC acquired a new stake in shares of Eyenovia in the second quarter valued at about $3,601,000. Vanguard Group Inc. boosted its holdings in Eyenovia by 25.2% in the first quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock valued at $1,765,000 after acquiring an additional 360,924 shares during the last quarter. BNP Paribas Financial Markets increased its position in Eyenovia by 1,444.4% during the 1st quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock valued at $217,000 after purchasing an additional 205,390 shares during the period. SkyView Investment Advisors LLC bought a new position in Eyenovia during the 2nd quarter worth approximately $87,000. Finally, Ground Swell Capital LLC acquired a new position in shares of Eyenovia in the 2nd quarter worth approximately $27,000. 25.84% of the stock is owned by institutional investors.

Eyenovia Trading Up 2.4 %

NASDAQ EYEN traded up $0.01 during trading hours on Friday, hitting $0.53. 79,210 shares of the company’s stock were exchanged, compared to its average volume of 1,209,849. The firm has a market cap of $28.54 million, a price-to-earnings ratio of -0.69 and a beta of 1.73. The stock has a 50-day simple moving average of $0.53 and a 200 day simple moving average of $0.72. The company has a current ratio of 0.46, a quick ratio of 0.27 and a debt-to-equity ratio of 3.72. Eyenovia, Inc. has a 1-year low of $0.37 and a 1-year high of $2.57.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $1.38 million. Eyenovia had a negative return on equity of 547.46% and a negative net margin of 116,506.25%. On average, equities analysts forecast that Eyenovia, Inc. will post -0.56 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on EYEN shares. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Eyenovia in a research report on Tuesday, August 13th. William Blair raised shares of Eyenovia to a “strong-buy” rating in a research report on Friday, August 30th.

Insider Buying and Selling

In related news, CEO Michael M. Rowe purchased 50,000 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was purchased at an average cost of $0.57 per share, with a total value of $28,500.00. Following the completion of the purchase, the chief executive officer now owns 82,927 shares in the company, valued at approximately $47,268.39. This trade represents a 100.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.10% of the stock is owned by insiders.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.